Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein

Bactericidal/permeability-increasing protein (BPI) is a cationic antimicrobial protein produced by polymorphonuclear leukocytes, that specifically interacts with and kills Gram-negative bacteria. BPl competes with lipopolysaccharide-binding protein (LBP) secreted by liver cells into blood plasma for...

Full description

Saved in:
Bibliographic Details
Main Authors: J.-O. Häggblom, A. B. Jokilammi-Siltanen, H. Peuravuori, T. J. Nevalainen
Format: Article
Language:English
Published: Wiley 1996-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/S0962935196000087
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850217034139303936
author J.-O. Häggblom
A. B. Jokilammi-Siltanen
H. Peuravuori
T. J. Nevalainen
author_facet J.-O. Häggblom
A. B. Jokilammi-Siltanen
H. Peuravuori
T. J. Nevalainen
author_sort J.-O. Häggblom
collection DOAJ
description Bactericidal/permeability-increasing protein (BPI) is a cationic antimicrobial protein produced by polymorphonuclear leukocytes, that specifically interacts with and kills Gram-negative bacteria. BPl competes with lipopolysaccharide-binding protein (LBP) secreted by liver cells into blood plasma for binding to lipopolysaccharide (LPS) and thus reduces the proinflammatory effects of LPS. We have developed a time-resolved fluoroimmunoassay for BPI and measured the concentration of BPI in human serum and plasma samples. The assay is based on a rabbit antibody against recombinant BPI. This antibody specifically adheres to polymorphonuclear leukocytes in immunostained human tissues. The difference in the serum concentration of BPI between unselected hospitalized patients with and without an infection was statistically significant. The mean concentration of BPI in serum samples was 28.3 μg/l (range 1.64–132, S.D. 26.8, n = 83). In contrast, there was no difference between the two groups in the BPI levels in plasma samples. For all individuals tested, BPI levels were consistently higher in plasma samples compared to the matched serum samples. The mean concentration of BPI in plasma samples was 52.3 μg/l (range 0.9–403, S.D. 60.6, n = 90). There was a positive correlation between the concentration of BPI and the white blood cell count as well as between the BPI concentration and C-reactive protein (CRP) in serum samples. In conclusion, the present study demonstrates that BPI can be quantified reliably by time-resolved fluoroimmunoassay in human serum samples.
format Article
id doaj-art-2f9c6ed42a254d5b99afe4106a9847fa
institution OA Journals
issn 0962-9351
1466-1861
language English
publishDate 1996-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-2f9c6ed42a254d5b99afe4106a9847fa2025-08-20T02:08:09ZengWileyMediators of Inflammation0962-93511466-18611996-01-0151475010.1155/S0962935196000087Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing proteinJ.-O. Häggblom0A. B. Jokilammi-Siltanen1H. Peuravuori2T. J. Nevalainen3Department of Pathology, University of Turku, Kiinanmyllynkatu 10, Turku FIN-20520, FinlandDepartment of Pathology, University of Turku, Kiinanmyllynkatu 10, Turku FIN-20520, FinlandDepartment of Pathology, University of Turku, Kiinanmyllynkatu 10, Turku FIN-20520, FinlandDepartment of Pathology, University of Turku, Kiinanmyllynkatu 10, Turku FIN-20520, FinlandBactericidal/permeability-increasing protein (BPI) is a cationic antimicrobial protein produced by polymorphonuclear leukocytes, that specifically interacts with and kills Gram-negative bacteria. BPl competes with lipopolysaccharide-binding protein (LBP) secreted by liver cells into blood plasma for binding to lipopolysaccharide (LPS) and thus reduces the proinflammatory effects of LPS. We have developed a time-resolved fluoroimmunoassay for BPI and measured the concentration of BPI in human serum and plasma samples. The assay is based on a rabbit antibody against recombinant BPI. This antibody specifically adheres to polymorphonuclear leukocytes in immunostained human tissues. The difference in the serum concentration of BPI between unselected hospitalized patients with and without an infection was statistically significant. The mean concentration of BPI in serum samples was 28.3 μg/l (range 1.64–132, S.D. 26.8, n = 83). In contrast, there was no difference between the two groups in the BPI levels in plasma samples. For all individuals tested, BPI levels were consistently higher in plasma samples compared to the matched serum samples. The mean concentration of BPI in plasma samples was 52.3 μg/l (range 0.9–403, S.D. 60.6, n = 90). There was a positive correlation between the concentration of BPI and the white blood cell count as well as between the BPI concentration and C-reactive protein (CRP) in serum samples. In conclusion, the present study demonstrates that BPI can be quantified reliably by time-resolved fluoroimmunoassay in human serum samples.http://dx.doi.org/10.1155/S0962935196000087
spellingShingle J.-O. Häggblom
A. B. Jokilammi-Siltanen
H. Peuravuori
T. J. Nevalainen
Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein
Mediators of Inflammation
title Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein
title_full Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein
title_fullStr Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein
title_full_unstemmed Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein
title_short Time-resolved fluoroimmunoassay for bactericidal/permeability-increasing protein
title_sort time resolved fluoroimmunoassay for bactericidal permeability increasing protein
url http://dx.doi.org/10.1155/S0962935196000087
work_keys_str_mv AT johaggblom timeresolvedfluoroimmunoassayforbactericidalpermeabilityincreasingprotein
AT abjokilammisiltanen timeresolvedfluoroimmunoassayforbactericidalpermeabilityincreasingprotein
AT hpeuravuori timeresolvedfluoroimmunoassayforbactericidalpermeabilityincreasingprotein
AT tjnevalainen timeresolvedfluoroimmunoassayforbactericidalpermeabilityincreasingprotein